

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 2666)

PARTIAL EXERCISE OF PUT OPTION BY THE HOLDER OF US\$150,000,000 GUARANTEED CONVERTIBLE BONDS DUE 2026

This announcement is made by Genertec Universal Medical Group Company Limited (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

References are made to the Company’s announcements dated 29 December 2020 and 25 March 2021 and the Company’s circular dated 14 January 2021 (the “**Circular**”) in relation to the issuance of US\$150,000,000 guaranteed convertible bonds due 2026. Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Circular.

As disclosed in the Circular, pursuant to the terms and conditions of the Convertible Bonds, each Bondholder has the right to require the Company to redeem all or part of such Bondholder’s Convertible Bonds on the Put Option Date (i.e. 25 March 2024 or 25 March 2025) at 100.0 per cent. of their principal amount (together with interest accrued but unpaid up to the Put Option Date) by depositing at the designated office a duly completed and signed notice (the “**Put Option Exercise Notice**”) and the bond certificates evidencing the Convertible Bonds to be redeemed not more than 60 days and not less than 30 days prior to the Put Option Date.

On 22 February 2024, the Issuer (being Genertec Universal Medical Development (BVI) Co., Ltd., a wholly-owned subsidiary of the Company) received the Put Option Exercise Notice from CCP Leasing II Limited in respect of US\$60,000,000 in aggregate principal amount of the Convertible Bonds (the “**Put Bonds**”), together with the relevant interest accrued but unpaid up. Accordingly, the Issuer is required to redeem the Put Bonds on 25 March 2024.

As at the date of this announcement, the total number of the Company’s issued shares is 1,891,539,661 Shares. Following the redemption and cancellation of the Put Bonds, Convertible Bonds in the principal amount of US\$90,000,000 will remain outstanding, and the maximum number of Shares that will be issued upon conversion of all the outstanding Convertible Bonds is 114,809,852 Shares, representing approximately 6.07% of the Company’s issued share capital as at the date of this announcement and approximately 5.72% of the Company’s issued share capital as enlarged by the issuance of such Conversion Shares (assuming that there is no other change to the Company’s issued share capital).

By order of the Board
**Genertec Universal Medical Group Company
Limited**
通用環球醫療集團有限公司
Peng Jiahong
Chairwoman of the Board

Beijing, PRC, 22 February 2024

As at the date of this announcement, the executive directors of the Company are Ms. Peng Jiahong (Chairwoman), Mr. Wang Wenbing and Ms. Wang Lin; the non-executive directors of the Company are Mr. Chan Kai Kong (Vice-chairman), Mr. Tong Chaoyin, Mr. Xu Ming and Mr. Zhu Ziyang; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.